Titre du document / Document title

Comprehensive therapy in osteoporosis using a single drug : From ADFR to strontium ranelate

Auteur(s) / Author(s)

MANETTE C. ⁽¹⁾ ; COLLETTE J. ⁽¹⁾ ; SARLET N. ⁽¹⁾ ; TANCREDI A. ⁽²⁾ ; ZEGELS B. ⁽¹⁾ ; REGINSTER J.-Y. ^{(1 2)} ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, Liège, BELGIQUE
⁽²⁾ Bone and Cartilage Metabolism Unit, University of Liège, Liège, BELGIQUE

Résumé / Abstract

In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated rat osteoclast, a preincubation of bone slices with strontium ranelate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. In a phase II dose ranging trial Strontium ranelate (500 mg, 1000 mg, 2000 mg/day) or placebo were given to 353 postmenopausal women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study, the annual increase in lumbar BMD of the group receiving 2000 mg of strontium ranelate was + 7.3%, a significant increase in bone alkaline phosphatase, over a 6-month period and a significant decrease in N-telopeptide crosslinks throughout the 2-year period were seen. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. The primary analysis of the SOTI study. evaluating the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patient experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture by 16% in the group treated with strontium ranelate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture by 36% was also demonstrated in the patients at high risk of hip fracture (age ≥74 years and Femoral Neck T score ≤-2.4 according to NHANES normative value). All these results suggest that strontium ranelate is a new, effective and safe treatment of vertebral and non-vertebral osteoporosis, with a unique mode of action.

Revue / Journal Title

Current medicinal chemistry   ISSN 0929-8673 

Source / Source

2006, vol. 13, n^o13, pp. 1585-1590 [6 page(s) (article)] (22 ref.)

Langue / Language

Anglais

Editeur / Publisher

Bentham Science, Oak Park, IL, ETATS-UNIS  (1994) (Revue)

Mots-clés anglais / English Keywords

Alkaline earth metal Compounds ; Bone disease ; Diseases of the osteoarticular system ; Human ; Pharmacokinetics ; Oral administration ; Woman ; Animal ; Experimental disease ; In vivo ; In vitro ; Postmenopause ; Bone defect ; Prevention ; Bioavailability ; Thiophene derivatives ; Carboxylate ; Organic salt ; Treatment ; Chemotherapy ; Osteoporosis ;

Mots-clés français / French Keywords

Métal alcalinoterreux Composé ; Ostéopathie ; Système ostéoarticulaire pathologie ; Homme ; Strontium ranélate ; Pharmacocinétique ; Voie orale ; Femme ; Animal ; Pathologie expérimentale ; In vivo ; In vitro ; Postménopause ; Perte substance os ; Prévention ; Biodisponibilité ; Thiophène dérivé ; Carboxylate ; Sel organique ; Traitement ; Chimiothérapie ; Ostéoporose ;

Mots-clés espagnols / Spanish Keywords

Metal alcalino-térreo Compuesto ; Osteopatía ; Sistema osteoarticular patología ; Hombre ; Farmacocinética ; Vía oral ; Mujer ; Animal ; Patología experimental ; In vivo ; In vitro ; Postmenopausia ; Pérdida substancia hueso ; Prevención ; Biodisponibilidad ; Tiofeno derivado ; Carboxilato ; Sal orgánica ; Tratamiento ; Quimioterapia ; Osteoporosis ;

Mots-clés d'auteur / Author Keywords

Osteoporosis ; treatment ; fractures ; strontium ranelate ;

Localisation / Location

INIST-CNRS, Cote INIST : 22999, 35400014250972.0070